Healthcare provider profile · identity verified

Ghasan M. Tabel, MD

Internal Medicine · CORONA, CA · NPI 1750458659

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	455	55
Eliquis	Apixaban	312	29
Pantoprazole Sodium	Pantoprazole Sodium	227	40
Amlodipine Besylate	Amlodipine Besylate	217	29
Levothyroxine Sodium	Levothyroxine Sodium	209	27
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	173	51
Metoprolol Tartrate	Metoprolol Tartrate	172	31
Levetiracetam	Levetiracetam	169	18
Sodium Chloride	0.9 % Sodium Chloride	163	38
Furosemide	Furosemide	162	32
Gabapentin	Gabapentin	149	27
Lisinopril	Lisinopril	143	20
Quetiapine Fumarate	Quetiapine Fumarate	121	19
Carvedilol	Carvedilol	116	20
Tamsulosin Hcl	Tamsulosin Hcl	115	17
Clopidogrel	Clopidogrel Bisulfate	96	13
Famotidine	Famotidine	89	14
Divalproex Sodium	Divalproex Sodium	86	13
Buspirone Hcl	Buspirone Hcl	85	suppressed
Diltiazem Hcl	Diltiazem Hcl	84	suppressed
Donepezil Hcl	Donepezil Hcl	74	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	72	12
Lactulose	Lactulose	69	18
Trazodone Hcl	Trazodone Hcl	65	12
Baclofen	Baclofen	61	suppressed
Mirtazapine	Mirtazapine	60	suppressed
Potassium Chloride	Potassium Chloride	60	16
Finasteride	Finasteride	59	suppressed
Hydralazine Hcl	Hydralazine Hcl	58	15
Midodrine Hcl	Midodrine Hcl	55	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	53	suppressed
Risperidone	Risperidone	52	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	51	suppressed
Omeprazole	Omeprazole	49	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	48	suppressed
Memantine Hcl	Memantine Hcl	47	suppressed
Fluticasone Propionate	Fluticasone Propionate	46	11
Humulin R	Insulin Regular, Human	46	11
Doxazosin Mesylate	Doxazosin Mesylate	45	suppressed
Enulose	Lactulose	43	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	43	11
Lantus	Insulin Glargine,hum.Rec.Anlog	42	suppressed
Sertraline Hcl	Sertraline Hcl	42	suppressed
Simvastatin	Simvastatin	42	suppressed
Humalog	Insulin Lispro	40	suppressed
Losartan Potassium	Losartan Potassium	40	suppressed
Diclofenac Sodium	Diclofenac Sodium	38	suppressed
Novolog Flexpen	Insulin Aspart	38	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	36	suppressed
Metformin Hcl	Metformin Hcl	35	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	33	suppressed
Latanoprost	Latanoprost	32	suppressed
Topiramate	Topiramate	32	suppressed
Epogen	Epoetin Alfa	31	suppressed
Benztropine Mesylate	Benztropine Mesylate	30	suppressed
Benazepril Hcl	Benazepril Hcl	29	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	29	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	28	suppressed
Heparin Sodium	Heparin Sodium,porcine	28	suppressed
Novolin R	Insulin Regular, Human	28	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Novolog	Insulin Aspart	27	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	27	suppressed
Allopurinol	Allopurinol	26	suppressed
Ceftriaxone	Ceftriaxone Sodium	26	16
Enalapril Maleate	Enalapril Maleate	26	suppressed
Vancomycin Hcl	Vancomycin Hcl	26	12
Xarelto	Rivaroxaban	26	suppressed
Amantadine	Amantadine Hcl	25	suppressed
Ertapenem	Ertapenem Sodium	25	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	25	suppressed
Multaq	Dronedarone Hcl	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	suppressed
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Aripiprazole	Aripiprazole	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	24	16
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Timolol Maleate	Timolol Maleate	23	suppressed
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	22	suppressed
Meropenem	Meropenem	21	suppressed
Tramadol Hcl	Tramadol Hcl	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	suppressed
Carbamazepine	Carbamazepine	20	suppressed
Divalproex Sodium Er	Divalproex Sodium	20	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	20	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Gemtesa	Vibegron	19	suppressed
Cefepime Hcl	Cefepime Hcl	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Micafungin	Micafungin Sodium	18	suppressed
Mupirocin	Mupirocin	18	suppressed
Pentasa	Mesalamine	18	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	17	suppressed
Glipizide	Glipizide	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Clonidine	Clonidine	16	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Metoprolol Succinate	Metoprolol Succinate	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Cephalexin	Cephalexin	14	14
Descovy	Emtricitabine/Tenofov Alafenam	14	suppressed
Megestrol Acetate	Megestrol Acetate	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Santyl	Collagenase Clostridium Hist.	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Glucagon Emergency Kit	Glucagon	12	suppressed
Glucagon Emergency Kit	Glucagon Hcl	12	suppressed
Levemir Flexpen	Insulin Detemir	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Tivicay	Dolutegravir Sodium	12	suppressed
Zafirlukast	Zafirlukast	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Insulin Aspart	Insulin Aspart	11	suppressed
Levofloxacin	Levofloxacin	11	suppressed
Nystatin	Nystatin	11	suppressed
Oxcarbazepine	Oxcarbazepine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error